Skip to main content

Chemoimmunotherapy + Spatially Fractionated RT and Deep Hyperthermia

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

  • RegistryNCT06546969
  • PhasePhase 1
  • StatusRecruiting
  • ConditionAdvanced Biliary Tract Cancer
  • SponsorUniversity of Maryland, Baltimore
How Chemoimmunotherapy + SFRT and Hyperthermia worksNCT065469691 min

What the film says

Read the transcript

This trial is for adults with advanced biliary tract cancer, including cholangiocarcinoma, who do not qualify for surgery.

The idea: add two treatments to standard chemoimmunotherapy with gemcitabine, cisplatin and durvalumab. One tumor gets a single dose of spatially fractionated radiation, then two sessions of deep hyperthermia, which heats the tumor.

This phase 1 study plans 15 patients and measures serious side effects and whether heating reaches its target. At the University of Maryland in Baltimore, Jason Molitoris leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06546969

    Adults; advanced biliary tract cancer incl. cholangiocarcinoma, not surgical; Added to standard gemcitabine, cisplatin, durvalumab; One lesion: single SFRT dose, then two deep hyperthermia sessions; Phase 1; 15 patients; serious side effects and heating target (+1 more lines)

The drug

What is being tested.

Administered to 1 measurable lesion on cycle 2-day 1

Deep hyperthermia alone will be delivered to the same lesion on cycle 3-day 1 and cycle 4-day 1

For this study, the drugs Gemcitabine, Cisplatin, and Durvalumab will be used. Chemoimmunotherapy will be delivered over 4 cycles for this study and can continue longer if the treating physician decides this is appropriate. Each cycle will last 3 weeks. Spatially fractionated radiation therapy (SFRT) SFRT is a form of radiation therapy that gives a single large dose of radiation to large tumors or tumors that do not qualify for surgery.

The study

How the trial runs.

This study is being done to see if the investigators can improve the outcome of patients with biliary tract cancer that do not qualify for surgery. This study will compare the effects, good and/or bad, of using a combination of standard of care chemoimmunotherapy, with the addition of radiation and deep hyperthermia.

In this study, participants will be receiving standard of care chemoimmunotherapy (gemcitabine, cisplatin, and durvalumab), radiation (spatially fractionated radiation therapy), and deep hyperthermia. Chemoimmunotherapy Chemoimmunotherapy is when chemotherapy drugs are combined with immunotherapy drugs. Chemotherapy uses different drugs to kill or slow the growth of cancer cells, whereas immunotherapy drugs are used to help the immune system attack cancer cells.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  • Provision of a signed and dated written ICF prior to any mandatory study-specific procedures, sampling, and analyses
  • Age ≥ 21 years at the time of screening
  • Histologically-confirmed, unresectable advanced or metastatic carcinoma of the biliary tract including intrahepatic or extrahepatic cholangiocarcinoma and gallbladder carcinoma
  • No prior systemic therapy for locally advanced, metastatic, or recurrent BTC (prior adjuvant capecitabine therapy is allowed as long as last treatment was ≥ 1 month before enrollment)
  • An ECOG performance status of 0-2 at enrollment

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.